🎯 Drug Targets

Browse 11 drug targets with druggability analysis, composite scores, and clinical context

11

Targets

0

High Druggability

0.55

Avg Score

15

Target Classes

Druggability Distribution

High: 0Medium: 3Low: 7Unknown: 0

Avg druggability score: 0.406

Clinical Pipeline

Approved: 5Phase III: 1Phase II: 2Phase I: 3Preclinical: 0

Total compounds: 39 · Approved: 18

Filtered by: class=transcription_factor — 11 results

NR3C1 Glucocorticoid receptor Approved

Transcription Factor Medium Druggability

Selective glucocorticoid receptor modulators (SRMs) or antagonists

FOXO1 Forkhead box protein O1 Phase I

Transcription Factor Medium Druggability

Small molecule modulation of protein-DNA interactions or cofactor binding

TFAM Transcription factor A, mitochondrial Approved

Transcription Factor Medium Druggability

Drugs targeting TFAM would enhance or modulate its transcriptional activity to increase mitochondrial DNA replication and gene expression, thereby boosting mitochondrial biogenesis and ATP production. Alternatively, indirect approaches activate upstream regulators like PGC-1α and SIRT1 to increase TFAM expression and activity.

PPARGC1A Peroxisome proliferator-activated receptor gamma c Approved

Transcription Factor Low Druggability

Small molecule modulator of transcriptional coactivator function

FOXO3 Forkhead box protein O3 Approved

Transcription Factor Low Druggability

FOXO3-targeting drugs modulate the PI3K/Akt/FOXO3 signaling pathway to promote FOXO3 nuclear translocation and transcriptional activity, enhancing autophagy, stress resistance, and apoptosis in cancer cells. Indirect activators increase FOXO3 expression or prevent its degradation, thereby amplifying cellular protective responses.

CLOCK Circadian Locomotor Output Cycles Kaput Approved

Transcription Factor Low Druggability

Modulation of circadian transcriptional activity through protein-protein interaction disruption

BMAL1 Basic Helix-Loop-Helix ARNT Like 1 Phase I

Transcription Factor Low Druggability

Small molecule modulator of circadian transcription

AHR Aryl hydrocarbon receptor Phase II

Transcription Factor Low Druggability

Small molecule modulators affecting ligand-dependent transcriptional activity

TARDBP TAR DNA-binding protein 43 Phase III

Transcription Factor Low Druggability

RNA-binding and transcription regulation, challenging for small molecule targeting

SREBF2 Sterol regulatory element binding transcription fa Phase II

Transcription Factor Undruggable Druggability

Small molecule modulators of transcriptional activity or protein-protein interactions

FOXP3 Forkhead box protein P3 Phase I

Transcription Factor Low Druggability

Transcription factor modulation - no direct small molecule binding